Study on Surface Esterification of Cellulose Nanocrystals Their and Lipid-Lowering Effect

被引:0
|
作者
Yang, Jiachuan [1 ]
Liu, Jianxia [1 ]
Zhang, Xiaochen [2 ]
机构
[1] Shanxi Datong Univ, Coll Agr & Life Sci, 405 Xingyun St, Datong 037009, Shanxi, Peoples R China
[2] Jilin Vocat & Tech Coll, Longjing, Peoples R China
关键词
Cellulose nanocrystal; esterification modification; fat; digestion; absorption; buckwheat fiber;
D O I
10.1080/15440478.2024.2410937
中图分类号
TB3 [工程材料学]; TS1 [纺织工业、染整工业];
学科分类号
0805 ; 080502 ; 0821 ;
摘要
With the rapid development of the economy and changes in dietary structure, there is an excessive intake of high sugar and high-fat foods. To address this issue, in this study, we grafted palmitic acid onto CNC in the form of ester groups and evaluated its adsorption performance. Research had found that among these three methods, the CDI catalytic method can successfully obtain esterification modified CNC while also taking into account its environmentally friendly and pollution-free characteristics. Compared with CNC, its adsorption capacity for oil had increased, with the maximum adsorption capacity increasing from 35.80 g/g to 46.91 g/g. Meanwhile, the degree of esterification substitution of esterification modified CNC was measured, and the result was 0.03. Especially, after adding CNC-PA, the hydrolysis of fat was significantly reduced during the simulated digestion in vitro, whilst the absorption of fat in the intestine was significantly inhibited. In vivo testing also confirmed that consuming a diet containing CNC-PA significantly reduced elevated levels of triglycerides (TG) compared to the high-fat control group while long-term feeding of a diet containing CNC-PA reduced weight and fat accumulation.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] LIPID-LOWERING THERAPY IN PERSPECTIVE
    THOMPSON, GR
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1988, 42 (02): : 61 - 64
  • [42] Pharmacoeconomics of lipid-lowering drugs
    Dean G. Smith
    Current Atherosclerosis Reports, 2003, 5 (1) : 67 - 72
  • [43] Lipid-lowering therapies in development
    Wierzbicki, AS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1405 - 1418
  • [44] Lipid-lowering drugs and cataract
    Bezin, J.
    Mansiaux, Y.
    Pariente, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 6 - 6
  • [45] Choice of lipid-lowering drugs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1042): : 117 - 122
  • [46] Lipid-lowering Therapies in Myositis
    Marisa C. Mizus
    Eleni Tiniakou
    Current Rheumatology Reports, 2020, 22
  • [47] Pharmacogenetics of lipid-lowering drugs
    Kivisto, K. T.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 47 - 47
  • [48] Carcinogenicity of lipid-lowering drugs
    Laws, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1480 - 1480
  • [49] MECHANISMS OF LIPID-LOWERING AGENTS
    SIRTORI, CR
    MANZONI, C
    LOVATI, MR
    CARDIOLOGY, 1991, 78 (03) : 226 - 235
  • [50] The Future of Lipid-Lowering Therapy
    van Zwol, Willemien
    Rimbert, Antoine
    Kuivenhoven, Jan Albert
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)